Clinical Trial Search Results
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for
At least 6 Months
At least 6 Months
This study is currently enrolling.
The purpose of the study is to evaluate daily oral doses of the study drug called venglustat compared to placebo: what is the effectiveness (how well it works) on symptoms of the Fabry disease, mainly neuropathic pain and abdom ...
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
This study is currently enrolling.
The purpose of this study is to evaluate the safety and efficacy of study drugs venetoclax and azacitidine compared to Best Supportive Care (no study medication) when given as maintenance therapy after allogeneic stem cell tran ...
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1
This study is currently enrolling.
This study will be recruiting patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative Breast Cancer whose tumors do not express PD-L1 or patients previously treated with Anti PD-(L)1 Agent ...
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and
Pembrolizumab Versus Treatment of Physician’s Choice and
Pembrolizumab in Patients With Previously Untreated, Locally Advanced,
Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors
Express PD-L1.
Pembrolizumab Versus Treatment of Physician’s Choice and
Pembrolizumab in Patients With Previously Untreated, Locally Advanced,
Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors
Express PD-L1.
This study is currently enrolling.
The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or spread when compared to chemot ...
ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
This study is currently enrolling.
The main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking luspatercept. The safety ...
ALLAY-HF: Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure
This study is currently enrolling.
To evaluate the safety and efficacy of the Alleviant ALV1 System in patients with chronic heart failure (HF) and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), who remain symptomatic despite a ...
Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
This study is currently enrolling.
Alzheimer’s Disease (AD): The purpose of this study is to look at whether BIIB080 (the study drug) can help people with Alzheimer’s Disease (AD), how safe it is, and how the body handles taking it (known as tolerability). Parti ...
An All Comers Registry for Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
This study is currently enrolling.
The purpose of the UNOS All Comers Registry is to collect standard of care clinical data from UNOS all comers who are transplanted with an EVLP lung treated with the XVIVO Perfusion System in order to assess the long-term perfo ...
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC)
This study is currently enrolling.
The primary objective of the study is to evaluate the long-term safety and tolerability of maralixibat.